Zoledronic acid blocks the interaction between breast cancer cells and regulatory T-cells

BMC Cancer
Hsien LiuTsun-Mei Lin

Abstract

Zoledronic acid (ZA), a nitrogen-containing bisphosphonate, inhibits osteoclastogenesis. Emerging evidence suggests that ZA has anti-tumor and anti-metastatic properties for breast cancer cells. In a mouse model of ZA-related osteonecrosis of the jaw, ZA administration was found to suppress regulatory T-cells (Tregs) function. Our previous reports also demonstrated ZA acted as an immune modulator to block Tregs. Manipulation of Tregs represents a new strategy for cancer treatment. However, the relationship among ZA, Tregs, and cancer cells remains unclear. In this study, we investigated the effects of ZA on the interaction of breast cancer cells and Tregs. The anti-tumor effect of ZA on triple negative breast cancer cell lines were validated by XTT, wound healing and apoptosis analysis. A flow cytometry-based assay was used to analyze the immunosuppressive effect of Tregs treated with media conditioned by breast cancer cells, and a transwell assay was used to evaluate the chemotactic migration of Tregs. Differential gene expression profile on MDA-MB-231 treated with ZA (25 μM) was analyzed by. microarrays to describe the molecular basis of actions of ZA for possible direct anti-tumor effects. Enzyme-linked immunosorbent assays ...Continue Reading

References

Feb 3, 2005·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Cory M RobinsonJoseph M Carlin
Nov 26, 2005·The Journal of Clinical Investigation·Jens DannullJohannes Vieweg
Jun 27, 2006·Journal of Immunotherapy·Udaya K LiyanageDavid C Linehan
Jul 14, 2006·Springer Seminars in Immunopathology·Rong-Fu Wang
Jul 25, 2006·Blood·Marc Beyer, Joachim L Schultze
Sep 20, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Simon ReadFiona Powrie
Jan 29, 2008·International Journal of Cancer. Journal International Du Cancer·Yoshiki MizukamiHideki Fujii
Aug 30, 2008·Therapeutics and Clinical Risk Management·Thomas J Polascik, Vladimir Mouraviev
Dec 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul SalamaBarry Iacopetta
Feb 24, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Adam W Mailloux, M Rita I Young
May 6, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Teruji TotsukaMamoru Watanabe
May 6, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Zuqiang LiuZhaoyang You
Sep 23, 2009·Annals of the New York Academy of Sciences·Andrew J Rech, Robert H Vonderheide
Dec 22, 2009·Pharmacogenetics and Genomics·Li GongTeri E Klein
Dec 24, 2009·Cancer Research·Zvi G FridlenderSteven M Albelda
Mar 5, 2010·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Takashi KikuiriSongtao Shi
Jul 15, 2011·The Journal of Immunology : Official Journal of the American Association of Immunologists·Barbara CastellaMassimo Massaia
Oct 11, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R ColemanN Bundred
Dec 4, 2012·Clinical and Experimental Immunology·K OleinikaA R Fraser
Nov 19, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M GnantUNKNOWN Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria
Dec 30, 2014·Oncotarget·Iris Chiara SalaroglioChiara Riganti
May 3, 2015·The Journal of Immunology : Official Journal of the American Association of Immunologists·Hyo Jin ParkSang-Jun Ha
Jan 21, 2016·The FEBS Journal·Chang LiuDario A A Vignali
Mar 1, 2014·Journal of Bone Oncology·Jamal ZekriSyed Mustafa Karim
Nov 27, 2016·BMC Immunology·Hsien LiuTsun-Mei Lin
Dec 17, 2017·Cancer Research·George C PrendergastAlexander J Muller
Feb 1, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R ColemanN Bundred

❮ Previous
Next ❯

Citations

Feb 26, 2020·Cells·Ahmad Adebayo IrekeolaRafidah Hanim Shueb
Feb 18, 2020·Oncotarget·Gnoni AntonioLicchetta Antonella
Sep 26, 2020·Frontiers in Oncology·Linyuan XueXiangyan Li
Jul 8, 2020·Cancers·Donatella AldinucciNaike Casagrande
Dec 25, 2019·Seminars in Cancer Biology·Ninh M La-BeckAlberto A Gabizon
Mar 26, 2021·Cancer Research·Christopher I LiKathleen E Malone

❮ Previous
Next ❯

Methods Mentioned

BETA
GTPases
ELISA
flow cytometry
PCR
Enzyme-linked immunosorbent assays
transgenic

Software Mentioned

AZURE
GraphPad
Prism

Related Concepts

Related Feeds

Cell Migration in Cancer and Metastasis

Migration of cancer cells into surrounding tissue and the vasculature is an initial step in tumor metastasis. Discover the latest research on cell migration in cancer and metastasis here.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Cell Migration

Cell migration is involved in a variety of physiological and pathological processes such as embryonic development, cancer metastasis, blood vessel formation and remoulding, tissue regeneration, immune surveillance and inflammation. Here is the latest research.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Breast Cancer: Therapeutic Approaches

Several different therapeutic approaches are used to treat breast cancer. These include chemotherapy, hormonal therapy, targeted therapy, and Immunotherapy. Discover the latest research on breast cancer therapeutic approaches here.